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Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by cognitive
dysfunction and memory loss, and pathologically characterized by amyloid-beta (Aβ) plaques
and inflammation. Recent research has shown that these Aβ plaques are also found in traumatic
brain injury (TBI) patients. This discovery has led to a proposed pathway leading from traumatic
brain injuries to dementia, more specifically AD. After a TBI, human granulin-A (GRN) and
interleukin-8 (IL8) are released and the number of elastases in the brain increases in response to
the inflammation response. IL8 is a cytokine that is released in acute inflammation responses,
and the levels of IL8 secreted are increased. Because of the presence of Aβ plaques in the brains
of TBI patients soon after the initial injury, it can be hypothesized that IL8 plays a role in the
aggregation of these Aβ plaques because of the inflammation response associated with this
cytokine, as well as the increased presence of IL8 in the brain. In order to examine the possible
interactions between IL8 and Aβ, the protein IL8 is being recombinantly expressed in E. coli,
and then purified using a nickel column. After purification, the protein will be characterized
using circular dichroism (CD), Ellman’s Assay, and mass spectrometry. The interactions
between IL8 and Aβ are being examine using ThioflavinT (ThT) fluorescence and SDS-PAGE.
When the results of the purification are examined, they show that the protein obtained was pure
and in the correct conformation. The interaction studies using ThT showed inhibition of Aβ
aggregation in the presence of IL8. Overall, the results from the research indicate that IL8 does
play an inhibitory role in the aggregation of Aβ.
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Introduction
Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder that is
characterized by cognitive dysfunction and memory loss, and is the most common form
of dementia. Pathologically, this disease is characterized by the presence of amyloid-β
(Aβ) plaques, neurofibrillary tangles, and neuronal death and loss of synapse functioning
(1). Memory loss and cognitive dysfunction, as well as the other symptoms of AD, are
caused by the deposition of the Aβ plaques in the brain that result in the death of neurons
and the atrophy of brain tissue. The plaques that are present in the brains of AD patients
are dense-core plaques, often referred to as “senile” plaques. These plaques are located
around the neurons and result in neuronal death; the death of the neurons causes the loss
of synaptic functioning and information is no longer able to be transmitted via these
synapses. Each Aβ plaque is composed of an accumulation of amyloid-β fibers formed
from the Aβ peptide, which is synthesized in the neuronal membrane in cholesterol-rich
regions and then released into the extracellular space (3). Aβ peptides are generated by
the proteolytic processing of amyloid precursor protein (APP) (9). A peptides typically
range from 37 to 43 amino acids among which Aβ40 peptide, and the Aβ42, are the
common ones (1,13).

Because the Aβ42 aggregates at a faster rate, it is commonly

observed in the prefibrillar aggregates and dense-core plaques (1). The process of Aβ
peptide aggregation nucleation-dependent in which a conformationally-altered aggregate
forms a nucleus for further aggregation. Typically, monomeric Aβ aggregates to forms a
nucleus which then seeds the formation of protofibrils and fibrils as shown in in Figure 1.
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Figure 1: Depicts the aggregation process of Aβ as it progresses from monomers to fibrils.

While Aβ plaques are believed to be one of the toxic species, another problematic
pathological characteristic of AD is the presence of these neurofibrillary tangles.
Neurofibrillary tangles cause damage to the neurons in the brains of Alzheimer’s disease
patients, and these tangles are found in and around the neurons and are large bundles of
abnormal fibers that lack membrane-binding; the individual fibers are found in pairs in
helical structures (1).

The major component of the neurofibrillary tangle is tau, a

soluble protein located in the cytoplasm (1, 2). Tau is a structural component of
microtubules, and mutated tau is found in the tangles. The formation of these plaques
results in neuronal damage, and this ultimately causes the neurons to die; when combined
with Aβ plaque deposition, neuronal death and damage leads to inflammatory responses
(2,4).
Inflammatory responses have been shown to play a role in Alzheimer’s disease.
The innate branch of the immune system is responsible for clearing the Aβ deposits, but
the plaques that the immune system can’t clear are responsible for the chronic
inflammation in AD (5,11,14). The complement pathway activated is the alternative
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pathway, but the classical complement pathway has also been found to operate in AD
(11, 19). The end result of both pathways, the formation of the membrane-attack
complex (MAC), is the same (19). The MAC “punches” holes in the membrane of the
targeted molecule, and the accumulation of these holes results in the death of the targeted
molecule; however, the death of the cell causes the contents to be released into the
environment and an inflammation response to occur. In healthy brains, formation of
MAC is a positive response because the foreign cell will lyse when enough MACs are
present; however, neuronal membranes with MACs that are located near Aβ plaques
results in damage to healthy cells (11). Alternative complement pathways do not need
antigen and antibody to bind in order to initiate the pathway, so it is usually activated by
foreign molecules on cell surfaces (19). Unlike the alternative pathway, the classical
complement pathway is an adaptive form of immunity. To activate classical
complement, antigen and antibody must bind (19). In the case of AD, the Aβ plaques
cause the alternative complement system to be activated because the senile plaques are
labeled foreign by the immune system. While the alternative complement pathway is
activated, the plaques are unable to be cleared, resulting in a chronic inflammatory
response. Aβ plaques, however, are not the only triggers for chronic inflammation in the
AD pathway. Accumulation of the neurofibrillary tangles also results in inflammation in
the brain of Alzheimer’s patients, and this typically occurs after failed attempts by the
innate immune system to remove the dead neurons (20). The combination of the senile
plaques and neurofibrillary tangles results in an overall inflammatory response in the
brain, causing an increase in neuronal death.
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Alzheimer’s disease is not the only neurodegenerative condition that involves an
inflammatory response. The Centers for Disease Control and Prevention describes a TBI
as an event that causes a penetration or contusion with the head that impairs normal brain
functioning (22). Traumatic brain injuries are also classified as neurodegenerative
disorders because of the damage that occurs to the brain tissue that causes degenerating
neural conditions (23). These injuries also exhibit inflammatory responses similar to
those seen in the AD pathway; TBI injuries are believed to initiate dementia, but the
molecular mechanism is unknown. The proposed pathway of TBI leading to dementia is
given in Figure 2.

Traumatic Brain Injury
PGRN
(Anti-inflammatory)
Elastases
(pro-inflammatory)

GRN peptides
(pro-inflammatory)

Promotes secretion

IL-8
(pro-inflammatory)

Aβ aggregation

Tau hyperphosphorylation

Figure 2: Proposed pathway
of TBI leading to dementia.

Cell death

Dementia

Immediately after a traumatic brain injury, interleukin-8 (IL8), one of the cytokines is
released along with a number of elastases. Progranulin (PGrn), an anti-inflammatory
protein is then cleaved by the elastases into smaller granulin (Grn) peptides (4). When an
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injury occurs, progranulin is upregulated and secreted (3,7).In a recent study, it was
found that progranulin is useful for wound repair and granulation, knowledge that could
be applied to treatment of inflammation (8). Granulins in turn may promote the
secretion of IL8, and granulin has recently been shown to be involved in Aβ aggregation
(7). Both IL8 and Grns are pro-inflammatory that are likely mediators in acute
inflammation-triggered Aβ aggregation. In this study we are focused on IL8 and its
interaction with Aβ. PGrn is 593 amino acid residues rich in cysteine. Granulin peptides
are growth factors like their precursor, progranulin, that are involved in wound repair,
tumor growth, and inflammation (4). Grn contains 12 cysteines and is approximately 6
kDa in size (16). Recently, it was discovered that granulin peptides promote the secretion
of IL8 (7). Since Grn peptides and IL8 are both pro-inflammatory, and AD involves an
inflammation response, it is thought that they could each play a role in the aggregation of
the Aβ plaques because of the presence of these dense-core plaques within hours of
traumatic brain injury. There is limited information about the IL8 involvement in AD;
because the peptides that secrete IL8 have been linked to AD, there may be an interaction
between IL8 and the Aβ.
IL8 is the pro-inflammatory pathway component of interest in this study, and it is
involved at two different stages and is believed to be involved in Aβ aggregation. IL8 is
a member of the chemokine alpha family, indicating that the genes for IL8 are found on
chromosome 4 (15). A chemokine is a chemotactic cytokine with a low molecular
weight and functions as an inflammation factor (12). Chemokines trigger inflammation
in a specific manner because they have a highly basic nature, causing them to attract
inflammatory cells that are in the bloodstream by interacting with the acidic extracellular
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components found in the matrix (15). The structure of the IL8 chemokine is a C-X-C
organization, which is two cysteines with an amino acid located between them, and the
entire structure consists of 72 amino acids (3, 15). The secondary structure of IL8
consists of two alpha helices and six beta sheets.
Because of the pro-inflammatory characteristics of IL8 and it upregulation in
traumatic brain injury, it is hypothesized that this protein plays a role in the aggregation
of Aβ in Alzheimer’s disease, and these potential interactions were examined using
various biochemical and biophysical methods, such as thioflavin-T (ThT) fluorescence
and SDS-PAGE.

7

Materials and Methods
Materials
The pET-15b expression vector containing the gene of IL8 protein was
synthesized at Florida State University, and the Aβ42 peptide was synthesized by the
Mayo Clinic peptide synthesis facility. SDS and ThT were purchased from Sigma
Aldrich, and the other compounds and chemicals use d were purchased from VWR, inc.
Methods
Interleukin-8 Expression
The protein was expressed by inoculating the BL21 E. coli with the plasmid. The
protein consisted of a His-tag and a thrombin cleavage site (Figure 3).

His-tag

IL-8
Thrombin cleavage site

Figure 3: Construct that was inserted into
11kDa
the vector with His-tag, IL8, and cleavage
site.

To start the cultures, 5 mL of Luria Bertani (LB) broth was added to a 15 mL culture
tube, then ampicillin was added in the concentration of 1 mg/mL. A cotton swab was
then used to obtain small quantities of frozen IL8 from the 2-5 colony in the -80⁰C, and
the cotton swab was placed in the culture tube overnight and left to shake in the 37⁰C
incubator. Next, 3 mL of the overnight culture was added to a 1 L culture of LB broth
with ampicillin and allowed to shake in the 37⁰C incubator until the optical density
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reached 0.6-0.8, and when this OD600 level is reached, the culture was induced using 0.5
mM isopropylthio-β-galactoside (IPTG) and then returned to the incubator for three more
hours. The cells were then placed in a 50 mL conical tube and centrifuged for 10minutes
at 9500 rpm using a Beckman Coulter Allegra X-22R centrifuge; the supernatant was
discarded and the pellet was kept for purification.
Protein Purification
After the cells had been expressed, the pellet is resuspended in 15 mL of 8 M
Urea, and 1 mM phenylmethanesulfonyl fluoride (PMSF), a serine protease inhibitor,
was added. The pellet was then vortexed to thoroughly resuspend the protein. Once the
protein was back in solution, the resuspended pellet was sonicated to break open the cells
and release the protein from the inclusion bodies. The sonication was performed using a
Misonix Ultrasonic Liquid Porcessor XL-2000 probe sonicator on ice for 30 seconds on
and 30 seconds off for a total of four cycles, and then the sonicated pellet shook for a
minimum of five hours on the orbital shaker. After at least five hours, the cell lysate was
centrifuged at 9500 rpm for 10 minutes in order to the remove the cell debris. The cell
debris formed the pellet and the resulting supernatant was saved because this is the
fraction that contained the protein.
Before the protein could be purified using the nickel column, the column had to
be equilibrated using 30 mL of Loading Buffer that contained 20 mM Tris pH 7.0, 100
mM NaCl, 10 mM Imidazole, and 2 M Urea. The supernatant was then loaded onto the
column, and the flowthrough was collected by slowly running the sample through the
column. This fraction was collected and stored at 4⁰C. 100 mL of Wash buffer was then
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run through the column, and this wash contained 20 mM Tris pH 7.0, 100 mM NaCl, 150
mM Imidazole, and 2 M Urea. The wash fraction was collected and stored at 4⁰C.
Following the wash, the protein was eluted by washing the column with 15mL of Elution
Buffer, and this consisted of 20 mM Tris pH 7.0, 100 mM NaCl, 400 mM Imidazole, and
2 M Urea. The elution fraction was collected and stored at 4⁰C. The final step of the
purification column was to rinse the column using 25 mL of Strip Buffer than contained
20 mM Tris, 250 mM EDTA, and 50 mM NaCl pH 8.0, and this fraction was also
collected and stored at 4⁰C.
The elution fraction was then dialyzed to remove the remaining Imidazole that
was in the protein sample, and this was done using a 3.5 kDA membrane. The fraction
was pipetted into the membrane and the membrane was secured from leaks before being
placed in the buffer. For this dialysis, the buffer used contained 20 mM Tris, 150 mM
NaCl, and 1 M Urea at pH 9.0, and the dialysis was conducted at 4⁰C. The buffer was
changed a minimum of three times before the protein was removed from the membrane
and stored in a conical tube at 4⁰C.
In order to ensure the purity of the protein collected, a gel was run using a 12%
polyacrylamide gel in 1X TRIS-glycine-SDS buffer, pH 6.8 at 80 V. The flowthrough,
wash, elution, dialyzed, and strip fractions were all run in the gel, and the samples
included 15 mL of the fraction and 5 mL of sample buffer. After the gel was run, it was
stained using GelCode Blue, obtained from Thermo Scientific, and the bands were
examined to determine if the protein was pure.
Purification Protocol Modifications
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Modifications to the purification protocol include shaking the supernatant on the
column overnight before collecting the flowthrough, and the concentrations of urea were
changed in the different buffers. Instead of using one wash to rinse the column, three
washes were used so the concentration of the urea could be gradually decreased. The
loading buffer was changed to include 20 mM Tris pH 7.0, 10 mM Imidazole, and 6 M
Urea pH 6.5. Wash 1 contained 20 mM Tris pH 7.0, 100 mM Imidazole, and 4 M Urea
pH 6.5; wash 2 was composed of 20 mM Tris, 150 mM Imidazole, and 2 M Urea pH 6.5;
and wash 3 contained 20 mM Tris pH 7.0 and 150 mM Imidazole.
Concentration of the Protein
Once the protein was purified, the concentration of the resulting fraction was
determined using Cary UV spectrophotometer. The Cary UV Scan program was used to
obtain a baseline and then the concentration of the protein. The baseline sample was 70
µL of the dialysis buffer, and the protein sample was 70 µL of the dialyzed protein. For
both samples, the absorbance was set at 280 nm. The graph of the scanned dialyzed
protein was used to calculate the concentration. A line was drawn from the flattest part
on the right-hand side of the graph to the y-axis and a line was drawn parallel to the yaxis at the 280 nm mark. The length of the line from the peak to where it intersects the
bottom line was measured in millimeters, and the distance between two numerical points
on the y-axis was measured in millimeters. The length of the line from the peak to the
bottom line was divided by the distance between the two points on the y-axis, and this
value was multiplied by the value that separated the points on the y-axis; the calculated
value was then divided by the known extinction coefficient, 7240.
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Ellman’s Assay
The Ellman’s Assay was done following the Thermo Scientific protocol for
Quantifying Sulfhydryl Groups Based on Molar Absorptivity. For this procedure, a
reaction buffer containing 0.1 M sodium phosphate pH 8.0 and 1 mM EDTA was made,
and an Ellman’s reagent solution solution was prepared by dissolving 4 mg Ellman’s
reagent in 1 mL of the prepared reaction buffer. A baseline sample containing 5 µL of
Ellman’s reagent, 250 µL reaction buffer, 20 µL of Tris, and 5 µL of water was prepared
and incubated at room temperature for five minutes. The sample containing the protein
was prepared using 5 µL of Ellman’s reagent, 250 µL of reaction buffer, 20 µL IL8, and
5 µL of water, and this sample was also incubated at room temperature for five minutes.
The spectrophotometer was set to scan from 350 nm to 450 nm, and the instrument was
calibrated using the baseline sample before running the protein sample. After cleaning
the cuvette, the protein sample was pipetted into the cuvette and the absorbance was
measured. The graph was printed out and the concentration of cysteines in the sample
was calculated by drawing a line parallel to the x-axis following the flattest region of the
curve and intersecting as many points along the line as possible. A line parallel to the yaxis was then drawn at the 412 nm wavelength, and the length of this line to where it
intersected the previously drawn line was measured in millimeters. The distance between
two of the absorbance units on the y-axis was then measured in millimeters. The length
of the line at 412 nm was divided by the distance between the two points on the y-axis,
and this is multiplied by the difference in numerical value between the points on the yaxis. After this value was calculated, the value was divided by the extinction coefficient
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of 2-nitro-5-thiobenzoic acid (TNB), 14,150 M-1cm-1, and the value was converted into
micromolar to examine the concentration.
Circular Dichroism
Circular Dischroism (CD) was performed using a Jasco J-815 spectropolariometer
that was set to monitor continuously from 190 nm to 260 nm, and each sample was run
three times and the values averaged. The samples were placed in a 0.1 cm quartz cuvette,
and 140 µL of each sample, Aβ control, IL8 control, and Aβ/IL8 interaction, was used to
examine the secondary structure.
Mass Spectrometry
MALDI-TOF mass spectrometry was performed by spotting a mass spectrometry
plate with the IL8 sample. The spectrometer was used to examine the molecular weight
of IL8 in order to confirm the purity of the protein.
Thioflavin-T Fluorescence
ThT Fluorescence was monitored using a Cary Eclipse fluorescence
spectrophotometer that was set to an excitation wavelength of 450 nm, emission
wavelength of 482 nm, and slit widths of 10 nm. Samples were made for an Aβ control,
IL8 controls, and Aβ/IL8 interaction samples. The Aβ control 25 µM Aβ, 50 mM NaCl,
and was filled to 100 µL with Tris pH 7.0. The IL8 controls were done in concentrations
of 12.5 µM, 24 µM, and 50 µM, and each contained 50 mM NaCl and were filled to a
total volume of 100 µL with Tris pH 7.0. In order to determine the fluorescence of each
sample, a 1 cm quartz microcuvette was filled with 70 µL of 10 µM ThT and 5 µL of a
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sample. The fluorescence spectrum was calculated and the absorbance at 0.5 A.U. was
recorded. The fluorescence was taken for each sample every 24 hours, with the samples
being stored at 37⁰C, and the points were plotted on a graph to examine the interactions.
SDS-Page and Silver Stain
The gels used in the polyacrylamide gel electrophoresis were handmade 12%
polyacrylamide gels, and the gels were run at 80 V in 1X Tris-Glycine-SDS, pH 6.8
buffer. The samples contained 5 µL of 4x sample buffer and 15 µL of the sample being
examined. When a silver stain was being used with the gel, an unstained marker was
used.
For a silver stain, the staining kit was purchased from Thermo Scientific and the
Thermo Scientific protocol was followed in the development of the gel. The gel was
washed in nanopure water for two five minutes washes, placed in silver stain fixing
solution for fifteen minutes, washed with 10% ethanol solution for two five minute
washes, rinsed with nanopure water for two more five minute washes, treated with
sensitizing solution for one minute, rinsed with water for two one minute washes,
incubated in working stain for thirty minutes, rinsed with water for two twenty second
rinses, and then placed in developing solution. The developing solution was left on the
gel until the bands were clearly visible, then the developing solution was replaced with
silver stain stop solution.
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Results
Protein Purification
After the protein was expressed in the E. coli cells, the cells were lysed and
centrifuged to collect the protein, and the cells were clarified for Ni-affinity purification
as described in the Materials and Methods. The ability to obtain a pure protein was
confirmed using SDS-PAGE, and this was done after each purification using the fractions
collected- flow through, wash 1, wash 2, wash 3, elution, strip, and dialysis. Figure 4
shows the purification performed in Tris using the Tris purification protocol. While there
is a small amount of protein present in several fractions, the majority of the protein is
located in the desired fraction, which was the elution fraction. The figure also shows that
the protein sample is pure, and this is able to be determined by the absence of other bands
in the elution and dialyzed sample lanes and the presence of bands around 11 kDa.

1

2

3

4

5

6
Figure 4: SDS-PAGE gel show results
for the Ni column affinity purification.
Column 1- Elution fraction
Column 2- Wash 3
Column 3- Wash 2
Column 4- Wash 1
11kDa Column 5- Flow through
9.5kDa Column 6- Marker
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Once the purity of the protein was confirmed, the concentration of the protein was
calculated using UV spectroscopy, and the spectrum obtained is shown in figure 5.

Figure 5: UV
spectroscopy spectrum
showing absorption of
protein sample used to
determine the
concentration of the
protein.

The concentration was calculated to be 26.89 µM, and while this concentration
could be used to run minimal experiments, a higher concentration was desired. To
increase the concentration, the protein was concentrated using an Amicon® centrigugal
concentrators (Millipore Inc) with a molecular weight cutoff at 3.5 kDa. A membrane
with this molecular weight limit was used because the next size was 10 kDa, and this
molecular weight is too close to the molecular weight of interleukin-8 and some of the
protein could have been lost in the process. After concentration, the calculation was
determined to be 100 µM.
IL8 Characterization
Interleukin-8 contains four cysteines that are paired with one another- Cys-7 binds
Cys-4 and Cys-9 binds Cys-50. The Ellman’s Assay was used to determine if all four of

16

these cysteines were bound and that there were no free cysteines in the protein. When
there are free cysteines in a compound, the TNB2- binds to the cysteine and this causes
fluorescence; when there are no free cysteines, there isn’t anything for the TNB 2- to bind
to and there isn’t anything to fluoresce. Because all of the cysteines are bound in IL8, it
was expected that there would not be any fluorescence and the absorbance would be zero
at 412 nm, the wavelength TNB2- absorbs at. The spectrum, figure 6, showed that there
was no absorbance at 412 nm, confirming that all four of the cysteines in the protein were
bound.

Figure 3: Spectrum of Ellman’s
Assay on purified IL8 sample.
Wavelength of interest in 412nm,
wavelength TNB2- fluoresces at,
and the curve at this wavelength
is showing no free cysteines.

Circular dichroism was performed on the sample in order to examine the
secondary structure of the protein. The predicted secondary structure of the protein
included two alpha helices and six beta sheets, but the CD spectrum, shown in figure 7,
did not show the defined peaks and valleys that were expected to correspond with the
alpha helices and beta sheets in the IL8 control. Certain minima correspond with
particular structures- 208 nm and 222 nm are alpha helices and 216 nm is a beta sheet.
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Figure 7: CD of IL-8 control with
minima at 224nm and 205nm.

Wavelength (nm)

The observed minima in this CD spectrum are 224 nm and 205 nm, which are very close
to the predicted minima for the two alpha helices present in the IL8 secondary structure;
however, because there are two secondary structures in the protein, one, the alpha helix,
shows up more predominantly than the other.
Mass Spectrometry
The largest peak on the spectrum, shown in figure 8, is the molecular ion peak
and shows the highest mass present in the sample, and the largest peak on this graph is at
11.484 kDa. This value corresponds with the molecular weight of the uncleaved IL8
protein, which has a molecular weight 11.5 kDa.
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Figure 8: Spectrum for mass spectrometry confirming purity of IL8.

IL8 and Aβ Interactions
ThioflavinT fluorescence was used to examine the interactions between Aβ and
IL8 over time by measuring the changes in fluorescence that occurred because of
fibrilization. Aβ and IL8 controls were used to monitor the aggregation that occurred in
the individual samples in order to compare these aggregation levels to the aggregation
levels measured in the Aβ and IL8 samples. The IL8 controls increased in concentration
from 12.5 uM to 25 uM to 50 uM, and this same increase in sample concentration was
used in the Aβ and IL8 samples. The 12.5 uM IL8/Aβ sample was 0.5:1, the 25 uM
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IL8/Aβ sample was 1:1, and the 50 uM IL8/Aβ sample was 2:1. The changes in
fluorescence were measured for all of the samples over 160 hours and the aggregation
levels were compared, and the results are shown in figure 9.

Figure 9: Aβ and IL8
aggregation over 160hours. The
spectrum shows the Aβ and IL8
controls, as well as the
incubations containing Aβ/IL8.

The fluorescence values increase as the level of aggregation increase, so higher A.U.
values correspond to more aggregation. This occurs because the ThT binds to the
amyloid protein and immobilizes one of the bonds, resulting in fluorescence. As the
number of amyloid proteins in the aggregate increases, the amount of ThT that is bound
causes an increase in the fluorescence.
When comparing the aggregation rates of the Aβ control, IL8 controls, and
Aβ/IL8 incubations, it is clear that the IL8 controls and the Aβ/IL8 incubations at all
three of the concentrations had very similar aggregation rates. Comparing this to the Aβ
control, it can be seen that there is inhibition of aggregation occurring in the Aβ/IL8
samples because the fluorescence levels in these samples are much lower than the
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fluorescence levels of the Aβ control. The changes in concentration do not appear to
cause any change in the inhibition level.
Precipitation was seen in the Aβ/IL8 interaction samples, but not in the Aβ
control or IL8 control. Because the precipitation was only present in the interaction
sample, a gel was run in order to determine if the precipitation was caused by an
interaction between the two proteins. The sample containing the precipitation, Aβ/IL8
interaction, was centrifuged at 9500 rpm for twenty minutes to spin the precipitation into
a pellet. The supernatant was then collected and the pellet was resuspended in 150 µL of
dialysis buffer. A gel was loaded with two sets of the samples, which were supernatant,
resuspended pellet, IL8 control, and Aβ control, and after the SDS-PAGE was complete,
the gel was split in half for silver stain and Western blotting. Figure 9 shows the results
of the silver stain gel.

Figure 9: Silver stain gel used to
examine the components of
precipitation in the Aβ/IL8 interaction
sample.

11kDa
9.5kDa

3.5kDa

Lane 1- Marker
Lane 2- Aβ control
Lane 3- IL8 control
Lane 4- Resuspended pellet
Lane 5- Supernatant
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The silver stain gel shows only Aβ monomer in the Aβ control found in lane 2, and lane 3
only shows IL8 in the IL8 control. The resuspended pellet sample in lane 4, however,
shows only one of the two interleukin-8 bands, the Aβ monomer band, and another band
much higher on the gel around 20 kDa. Lane 5 has the two interleukin-8 bands and the
Aβ monomer band. The band that appears at 20 kDa in the resuspended pellet sample is
mostly likely an IL8 dimer.
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Discussion
Purification
In order for the interaction studies to provide useful data, the IL8 used in the
aggregation reactions had to be pure so that the interactions between Aβ and IL8 could be
examined without the data being confounded by other proteins or cellular debris in the
sample. The purity of the IL8 was examined using SDS-PAGE, and the location of a
singular band at 11.5 kDa in the elution sample confirmed that the sample contained only
the desired IL8. The molecular weight of IL8 is 11.5 kDa, so the presence of the band
equal with the 11.5 kDa marker band and lack of any other bands in the sample made it
possible to conclude that the protein was purified.
The results present in this research project were achieved using IL8 that was
purified using the 20 mM Tris pH 7.0 buffer and the modified 20 mM Tris pH 7.0 buffer,
but the Tris protocol was not the only buffer protocol tested for protein purification.
Because of precipitation issue, the buffer for the purification was changed from Tris to 20
mM phosphate buffered saline (PBS) pH 6.5 based on a study conducted by Furuta et al
(23). When the Tris was used in the purification, there was so much precipitation that the
quantity and concentration of the purified protein was unusable. Research was done on
different purification protocols for IL8 and a protocol was found to have used 20mM PBS
pH 6.5 as the buffer. After switching the purification buffer to PBS, the precipitation
issues in the purification were solved and the resulting protein was obtained in higher
quantity and concentration; however, precipitation was still an issue in the IL8/Aβ
samples used for the ThT experiment. A final change was made to the purification
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protocol and the buffer was changed back to 20 mM Tris pH 7.0, but the concentrations
of urea were altered. Instead of one wash with 2 M urea, three washes using 6 M, 4 M,
and 2 M, respectively, were used, and this was done so the protein could refold at a
slower rate and prevent the precipitation. The protein had to be refolded due to the
incubation at 8M urea that was done to remove the protein from the inclusion bodies. In
each of the column washes, the urea concentration was decreased, but the imidazole
concentration was increased, and this was done to compete with the bound His-tag.
Imidazole concentrations were constantly increased to elute to protein from the nickel
affinity column. When the gel is examined for the purification using the modified Tris
protocol, protein can be seen in fractions other than the elution fraction. This loss of
protein slightly decreases the quantity and concentration of the protein in the elution
sample, but the amount lost is negligible. While this PBS protocol was based on a
purification method used by Furuta et al, the concentrations obtained in this study were
lower than those outlined in the study, and the precipitation issues were not encountered
in the previous study.
Characterization of IL8
Ellman’s Assay was done to quantify the free cysteines in IL8, and the results of
this assay confirmed that there were not any free cysteines in the pure protein. This assay
does not, however, show if the cysteines are bound to the correct cysteine. Cys-7 binds
to Cys-4 and Cys-9 binds to Cys-50 in a correctly folded protein. Based on the results of
this characterization experiment, we can conclude that there are the proper number of
disulfide bonds in the purified protein, but not that the correct pairing has occurred.
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Circular Dichroism was used to examine the secondary structure of IL8 to make
sure the protein was in the proper conformation. When the spectrum is examined, the
two minima for the alpha helices were observed.
Aβ and IL-8 Interactions
ThT fluorescence was used to monitor aggregation in the samples over time. The
spectrum presented previously was obtained using IL8 that was purified using the
modified Tris protocol, and the results show clear inhibition of Aβ aggregation in the
Aβ/IL8 samples. The Aβ control curve closely follows, with the exception of the 68hr
point, the sigmoidal growth curve of Aβ. This curve consists of a lag phase, seen from
zero to fifty hours, a growth phase, seen from 50 to 160 hours, and the eventual stationary
phase, which had not yet been reached when this experiment was halted. The
concentration of the IL8 in the Aβ/IL8 interactions does not appear to make a significant
difference in inhibition, as demonstrated by the spectrum. This lack of concentration
dependence is significant because it shows that lower levels of IL8 in the brain have the
same effect as high protein concentrations, and this could be used to a therapeutic
advantage.
When similar aggregation studies were conducted using PBS as the purification
buffer, the inhibitory results seen in the initial Tris experiments were not replicated.
Instead, there was so much precipitation that accurate fluorescence reading could not be
obtained. Yet another set of aggregation studies was tried using the modified Tris
protocol, and while the results were similar to the initial Tris aggregation results,
precipitation was still an issue. Visible precipitation was seen in the Aβ/IL8 interaction
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sample within one hour of sample preparation. The aggregation in this sample was
examined using SDS-PAGE to determine the components of the precipitate.
When the silver stain gel containing the samples of the supernatant and
resuspended pellet from the precipitated Aβ/IL8 sample is examined, the resuspended
pellet sample shows an Aβ monomer band, a single IL8 band, and an additional band at
20 kDa. The supernatant sample only contains the expected two IL8 bands and the Aβ
monomer band. Based on the molecular weight of the 20 kDa band, it is believed that
this band is an IL8 dimer.
Along with ThT fluorescence, SDS-PAGE has been used to examine the
aggregation in the interaction samples. Using these gels, it has been found that IL-8
could possible undergo a conformational change after 48hours of incubation, and this is
conclusion was reached based on the presence of two bands, one at approximately 11kDa
and the other at 9kDa, after 48hours in the IL8 control sample. These two bands have
been seen in every sample containing IL8 after the 48hour mark.
Future work for this project includes performing the cleavage on IL8 to remove
the His-tag and examining the changes that occur in the protein, exploring the
conformational change that is indicated by the change in molecular weight, and examine
the precipitation issues caused by difference in buffer in pH.
Overall, the research suggests that IL8 plays an inhibitory role in the aggregation
of Aβ. The purification protocol using Tris buffer has been standardized, and once a
solution for the precipitation in the Aβ/IL8 samples has been found, additional studies
can be performed examining this inhibition.

26

Literature Cited
1. Selkoe, Dennis J. (2001) Alzheimer’s Disease: Genes, Proteins, and Therapy.
Physiol Reviews 81(2), 741-766
2. Haass, C., and Selkoe, D.J. (2007) Soluble protein oligomers in
neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide, Nat Rev
Mol Cell Biol 8, 101-112
3. Harada et al. (1994) Essential involvement of interleukin-8 (IL-8) in acute
inflammation. Journal of Leukocyte Biology 56, 559-564
4. Ahmed et al. (2007) Progranulin in frontotemporal lobar degeneration and
neuroinflammation. Journal of Neuroinflammation 4(7), 1-13
5. Gopcevic et al. (2007) Plasma Interleukin-8 as a Potential Predictor of Mortality
in Adult Patients with Severe Traumatic Brain Injury. Tohoku Journal of
Experimental Medicine 211, 387-393
6. Pereson et al. (2009) Progranulin expression correlates with dense-core amyloid
plaque burden in Alzheimer disease mouse models. Journal of Pathology 219,
173-181
7. Tolkatchev et al. (2008) Structure dissection of human progranulin identifies
well-folded granulin/epithelin modules with unique functional activities. Protein
Science 17, 711-724
8. He et al. (2003) Progranulin is a mediator of the wound response. Nature
Medicine 9, 225-229
9. Kuman-Singh, S. (2007) Cerebral amyloid angiopathy: pathogenetic mechanisms
and link to dense amyloid plaques. Genes, Brain and Behavior 7, 67-82

27

10. Walsh et al. (1997) Amyloid beta- protein fibrillogenesis. Detection of a
protofibrillar intermediate. Journal of Biological Chemistry 272, 22364-22372
11. Rogers, Joseph. (2008) The Inflammatory Response in Alzheimer’s Disease.
Journal of Periodontology 10, 1535-1543
12. Vendramini et al. (2011) Interleukin-8-251T> A, Interleukin-1α-889C > and
Apolipoprotein E polymorphisms in Alzheimer’s Disease. Genetics and
Molecular Biology 34 (1), 1-5
13. Friedrich et al. (2010) Mechanism of amyloid plaque formation suggests an
intracellular basis of Aβ pathogenicity. PNAS 107 (5), 1942-1947
14. Grammas, Paul. (2011) Neurovascular dysfunction, inflammation and endothelial
activation: Implications for the pathogenesis of Alzheimer’s Disease. Journal of
Neuroinflammation 26 (8), 1-12
15. Ghirnikar et al. (1998) Inflammation in Traumatic Brain Injury: Role of
Cytokines and Chemokines. Neurochemical Research 23 (3), 329-340
16. Bateman, A. , Bennett, H. P. J. (1998) Granulins: the structure and function of an
emerging family of growth factors. Journal of Endocrinology 158, 145-151
17. Lue et al. (1999) Soluble Amyloid β Peptide Concentration as a Predictor of
Synaptic Change in Alzheimer’s Disease. American Journal of Pathology 155
(3), 853- 862
18. Bateman, A., Bennett, H. P. J. (2009) The granulin gene family: from cancer to
dementia. BioEssays 31, 1245-1254
19. Kindt et al. (2007) Immunology. W. H. Freeman and Company. New York, NY.

28

20. Neher et al. (2011) Molecular meachanisms of inflammation and tissue injury
after major trauma-is complement the “bad guy”?. Journal of Biomedical
Science, 18:90.
21. Centers for Disease Control and Prevention. Injury Prevention and Control:
Traumatic Brain Injury. http://www.cdc.gov/traumaticbraininjury/. March 18,
2013. Date accessed March 28, 2013.
22. Ziebell, J. M., Morganti-Kossmmann, M. C. Involvement of Pro- and AntiInflammatory Cytokines and Chemokines in the Pathophysiology of Traumatic
Brain Injury. Neurotherapeutics: The Journal of the American Society for
Experimental Neurotherapeutics. 7, 22-30.
23. Furuta et al. (1989) Production and Characterization of Recombinant Human
Neutrophil Chemotactic Factor. Journal of Biochemistry. 106, 436-441.

